- 中文名稱
Anti-Human DLK-1/Pref-1
- 英文名字
- Anti-Human DLK-1/Pref-1
- 供應商
- ReliaTech
- 產品貨號
- 102-PA137
- 產品報價
- ￥詢價/200ug
- 產品說明書
- 點擊查看
- 購買方式
- 90%產品中國有現貨庫存。銀行轉賬、電匯、支票、現金，在線支付寶及網銀支付，或直接與我們電話聯系400-6800-868
- 產品新聞
- 背景資料
- Delta-like 1 (DLK1), also known as Pref-1 and FA1, is a transmembrane protein pertaining to the epidermal growth factor superfamily. DLK1 affects several differentiation processes, including adipogenesis, muscular and neuronal differentiation, bone differentiation, and haematopoiesis. Several reports support that DLK1 may operate as a non-canonical ligand of the NOTCH pathway. Since the NOTCH signaling pathway is essential for vascular development and physiology by controlling angiogenesis in pre- and post-natal life, it was reasoned that DLK1 could contribute to regulate this process in adult endothelial cells through the interaction with NOTCH receptors. It was found that overexpression of DLK1 inhibits migration and angiotube formation in mammalian vascular endothelial cells and disrupts normal embryonic vascularization in zebrafish. Genetic ablation of DLK1 in mice is associated with increased angiogenesis in vitro and with focal areas of retinal hyper-vascularization. Specific knockdown of the orthologous Dlk1 of zebrafish results in ectopic angiogenesis. Moreover, in a tumor angiogenesis model in zebrafish, suppression of Dlk1 promotes vessel migration towards the tumor cell mass. It was also found that the NOTCH signaling pathway is targeted by DLK1 in the context of angiogenesis and that DLK1 antagonizes NOTCH-dependent signaling in endothelial cells, while, in contrast, this signaling is enhanced in Dlk1-null mice. Collectively, these results revealed a previously unknown role for DLK1 in the vasculature as a regulator of NOTCH-mediated angiogenesis.
- 應用類型
- WB
- 免疫原
- 該Anti-Human DLK-1/Pref-1的詳細信息查看ReliaTech提供的產品說明書。
- 來源宿主
- Rabbit
- 反應性
- 該Anti-Human DLK-1/Pref-1的詳細信息查看ReliaTech提供的產品說明書。
- 保存建議
- 該Anti-Human DLK-1/Pref-1的詳細信息查看ReliaTech提供的產品說明書。
- 其他
- ReliaTech全稱為受體配體技術有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，總部位于德國不倫瑞克，是一家后基因組生物技術公司。ReliaTech主要專注于受體和配體的發(fā)現與研究。此外，ReliaTech也開發(fā)應用于血管與淋巴管生成研究的相關高品質試劑。目前ReliaTech提供近2800款產品，產品線主要包括重組蛋白(細胞因子、生長因子、可溶性受體)、抗體、ELISA試劑盒等。
- 注意
-
該頁面的中文產品信息的翻譯，僅供參考。準確的產品信息請以廠家的英文說明書為準。下單前，請瀏覽說明書確認。
-
